ライフサイエンスコーパス: SMR

1 SMR at 10 years was higher until age 75 year, predominat

2 SMR can increase or decrease in response to food availab

3 SMR devices are unique in their ability to provide mass-

4 SMR due to cancer was 0.89 (95% CI 0.83 to 0.97).

5 SMR for cardiovascular disease was significant only in P

6 SMR increased when individuals were switched to a high f

7 SMR was 9.4 at 5 years and 5.4 at 10 years.

8 SMRs demonstrate spatial clustering of alterations in mo

9 SMRs due to cardiovascular diseases, suicide, infection

10 SMRs for all cancers, heart disease, and diabetes were s

11 SMRs for cancer and liver disease (recurrent or transpla

12 SMRs ranged from 3.1 (95% CI, 2.1-4.3) for trauma to 8.7

13 SMRs reveal recurrent alterations across a spectrum of c

14 SMRs showed similar patterns, with ARD of zero (arrhythm

15 SMRs varied by race, with black men exhibiting lower rel

16 SMRs were broadly similar in different ethnic groups wit

17 SMRs were extracted.

18 (SMR; SMR for CLL, 2.6; 95% CI, 2.3 to 3.0; SMR for NHL, 2.3; 95% CI, 2.1 to 2.6).

19 ears in fast vs slow privatised towns: 1.13, SMR 0.83, 95% CI 0.77-0.88 vs 0.73, 0.69-0.77, respectiv

20 (expected deaths, 189; observed deaths, 141; SMR, 0.75; 95% CI, 0.63 to 0.88).

21 (expected deaths, 209; observed deaths, 242; SMR, 1.16; 95% CI, 1.02 to 1.31), but it was reduced amo

22 (95% CI 1.7-4.0), and 4.1 (95% CI 2.6-6.3), SMRs for hepatobiliary mortality were 42.3 (95% CI 20.3-

23 reached significance between age 30 and 39 (SMR, 4.0; 95% CI, 1.1-10.0).

24 4, 95% confidence interval (CI): 0.52, 0.55; SMR(spouses) = 0.52, 95% CI: 0.50, 0.55).

25 ortality was observed between age 40 and 59 (SMR, 1.79; 95% CI, 1.2-2.4), particularly in men.

26 03-1.56) and in women 60 to 69 years of age (SMR, 1.94; 95% CI, 1.22-3.08).

27 rate (74.8 per 100,000 person-years) and an SMR of 2.4 (95% CI, 2.4-2.5).

28 rate (403.2 per 100,000 person-years) and an SMR of 3.6 (95% CI, 3.5-3.6).

29 virus release, we identified mortalin as an SMR-specific cellular protein.

30 were expected and 383 were observed, for an SMR of 0.96 (95% confidence interval [CI], 0.87 to 1.06)

31 lore this proposition, we are using Hsmr, an SMR from Halobacter salinarum that dimerizes to extrude

32 as 1.62 (95% CI, 1.31-2.01) compared with an SMR in the CMV group of 0.76 (95% CI, 0.62-1.16).

33 as 2.00 (95% CI, 1.71-2.35) compared with an SMR in the CMV group of 0.85 (95% CI, 0.68-1.07).

34 rst-cousin (SMR, 1.85; 95% CI, 1.70-2.00 and SMR, 1.50; 95% CI, 1.29-1.73, respectively) relatives of

35 ond-degree (SMR, 4.31; 95% CI, 3.98-4.65 and SMR, 2.70; 95% CI, 2.30-3.14, respectively) and first-co

36 and estimated the rate of change of CMR and SMR over the past 50 years.

37 meta-analyses were used to summarize SIR and SMR for melanoma in any flight-based occupation.

38 Summary SIR and SMR of melanoma in pilots and cabin crew.

39 .5 (95% CI, 30.2 to 46.0), respectively, and SMRs of 2,301 (95% CI, 1,652 to 3,122) and 30.2 (95% CI,

40 odeling evaluated association between annual SMR change and volume change over preceding years.

41 Cox model-based SMRs were computed with and without adjustment for patie

42 Because SMR is an intrinsic consequence of LV dysfunction, causa

43 equence of LV dysfunction, causality between SMR and mortality should not be implied.

44 In 26 of 36 studies reporting LV function by SMR grade, increasing SMR severity was associated with w

45 nterval (CI): 11.3, 27.4], laryngeal cancer (SMR = 8.1; 95% CI: 3.5, 16.0), liver cancer (SMR = 2.5;

46 SMR = 8.1; 95% CI: 3.5, 16.0), liver cancer (SMR = 2.5; 95% CI: 1.6, 3.7), and chronic renal disease

47 of increased mortality from bladder cancer [SMR = 18.1; 95% confidence interval (CI): 11.3, 27.4], l

48 All-cause SMR was 2.56 (95% CI 2.47 to 2.66) in males and 3.06 (95

49 Pooled all-cause SMR was 2.80 (95% CI 2.74 to 2.87).

50 ophrenia were more than 3.5 times (all-cause SMR, 3.7; 95% CI, 3.7-3.7) as likely to die in the follo

51 s shelter during the study period (all-cause SMR: 1.35, 95% confidence interval (CI): 1.14, 1.59; dru

52 All-cause SMRs were significantly lower than that expected for res

53 than the general population for all causes (SMR 5.7, 95% CI 5.5-5.8), particularly non-AIDS infectio

54 eeks after release (for drug-related causes, SMR = 8.0, 95% confidence interval (CI): 5.2, 11.8; for

55 (c-statistics > 0.77) for prospective center SMRs and there was significant correlation between cente

56 Centers' SMR from the report card was highly predictive (c-statis

57 was significant correlation between centers' SMR from the report card period and the year following (

58 d CVD mortality occurred after chemotherapy (SMR, 1.36; 95% CI, 1.03 to 1.78; n=54) but not surgery (

59 rgan transplantation was higher in children (SMR, 84.61 [95% CI, 52.00-128.40]) and lower in patients

60 4-18.8), and primary sclerosing cholangitis (SMR 11.0-4.2), and deterioration in alcoholic liver dise

61 expected for patients with a history of CLL (SMR, 2.8; 95% CI, 2.2 to 3.4) or NHL (SMR, 2.1; 95% CI,

62 an expected for those with a history of CLL (SMR, 3.1; 95% CI, 2.2 to 4.3) or NHL (SMR, 1.9; 95% CI,

63 expected for patients with a history of CLL (SMR, 3.8; 95% CI, 2.5 to 5.9), but no difference was obs

64 For AIH, PBC, and PSC cohorts, SMRs for all-cause mortality were 2.1 (95% confidence in

65 s with aortic valve stenosis and concomitant SMR.

66 , 2.30-3.14, respectively) and first-cousin (SMR, 1.85; 95% CI, 1.70-2.00 and SMR, 1.50; 95% CI, 1.29

67 The number of deaths due to CVD (SMR = 1.02, 95% CI = 0.9-1.6) was nearly identical to th

68 also found to be elevated in second-degree (SMR, 4.31; 95% CI, 3.98-4.65 and SMR, 2.70; 95% CI, 2.30

69 ity was highest in the year after diagnosis (SMR 24.3, 95% CI 23.4-25.2).

70 ricted to the first year after TC diagnosis (SMR, 5.31; AER, 13.90; n=11) and included cerebrovascula

71 n=11) and included cerebrovascular disease (SMR, 21.72; AER, 7.43; n=5) and heart disease (SMR, 3.45

72 R, 21.72; AER, 7.43; n=5) and heart disease (SMR, 3.45; AER, 6.64; n=6).

73 infections (SMR 22-693) and kidney disease (SMR 13-45) across all indications, and from suicide in H

74 5% CI: 1.6, 3.7), and chronic renal disease (SMR = 2.0; 95% CI: 1.5, 2.8).

75 CI: 1.35, 2.61), and chronic renal disease (SMR = 3.11, 95% CI: 1.66, 5.32).

76 Particularly elevated SMRs were observed for chronic obstructive pulmonary dis

77 o liver disease were significantly elevated (SMR = 4.04, 95% CI = 2.76-5.70).

78 alignant neoplasms (n = 1124) were excluded (SMR, 1.93 [95% CI, 1.75-2.13]).

79 ved, which was 11 times the number expected (SMR, 10.7; 95% confidence interval [CI], 10.3-11.1).

80 ollow-up, which were 799 more than expected (SMR = 1.43, 95% confidence interval (CI): 1.38, 1.49).

81 cause mortality rate was less than expected (SMR(applicators) = 0.54, 95% confidence interval (CI): 0

82 In both FD and control fish, SMR was negatively correlated with preferred temperature

83 s using a shuttle-box, and then measured for SMR and AS at 10 degrees C, estimated by rates of oxygen

84 ree of SMR compared with patients not having SMR (21 studies, 21081 patients; RR, 1.96; 95% CI, 1.67-

85 e 23.1-9.2), hepatocellular carcinoma (HCC) (SMR 38.4-18.8), and primary sclerosing cholangitis (SMR

86 1985-1999 to 2000-2010 in hepatitis C (HCV) (SMR change 23.1-9.2), hepatocellular carcinoma (HCC) (SM

87 Several possible O3 sources can explain high SMR values on any given day.

88 We examine several cases with high SMR that are due to wildfire influence.

89 0.94), while postrelease mortality was high (SMR = 1.54, 95% CI: 1.48, 1.61).

90 mone and corticosterone content, and highest SMR, and these trait values are least affected by pond d

91 ence interval (CI): 5.2, 11.8; for homicide, SMR = 5.1, 95% CI: 3.2, 7.8).

92 We conclude that the identified SMR genes are part of a signaling cascade that induces a

93 ociated with 73% increased odds of improving SMR over time [odds ratio (OR) 1.73; 95% confidence inte

94 In SMR analyses of participants aged 50+, diabetes was sign

95 A reduction in SMR at cooler temperatures, coupled with a decrease in s

96 These shifts in SMR, in turn, were linked with individual differences in

97 Mutation frequencies in SMRs demonstrate that distinct protein regions are diffe

98 ficantly lower mortality while incarcerated (SMR = 0.66, 95% CI: 0.58, 0.76), while white men experie

99 enced elevated mortality while incarcerated (SMR = 1.28, 95% CI: 1.10, 1.48).

100 No significantly increased SMRs for diseases of the respiratory system or heart, or

101 porting LV function by SMR grade, increasing SMR severity was associated with worse LV function.

102 In LQTS type 2, we observed increasing SMRs starting from age 15 years, which just reached sign

103 There was no association between individual SMR, or the tendency to obtain oxygen from air when in i

104 levated premature mortality from infections (SMR 22-693) and kidney disease (SMR 13-45) across all in

105 interval: 0.55, 2.51; 8 deaths) and kidney (SMR = 1.44; 95% confidence interval: 0.69, 2.65; 10 deat

106 t described for several PPR proteins lacking SMR motifs.

107 al: 0.69, 2.65; 10 deaths) and for leukemia (SMR = 1.48; 95% confidence interval: 0.77, 2.59; 12 deat

108 articular during the first 10 years of life (SMR, 2.9; 95% CI, 1.5-5.1).

109 Expert judgments about likely SMR costs display an even wider range.

110 Existing estimates of likely SMR costs rely on problematic top-down approaches or bot

111 as increased risks for cancer of the liver (SMR = 1.27; 95% confidence interval: 0.55, 2.51; 8 death

112 Mortality during incarceration was low (SMR = 0.85, 95% CI: 0.77, 0.94), while postrelease morta

113 ts from the GELA study and registry in Lyon (SMR, 1.09; P = .71).

114 terval (CI): 1.05, 6.20), diabetes mellitus (SMR = 1.90, 95% CI: 1.35, 2.61), and chronic renal disea

115 sed significantly in the total group of men (SMR, 1.27; 95% CI, 1.03-1.56) and in women 60 to 69 year

116 VR at 2 institutions and presenting moderate SMR (mitral regurgitant volume 30 to 45 mL/beat) not con

117 ality ratios (SMRs) for all-cause mortality (SMR 1.14, 95% CI 0.65-1.85; p=0.67) or cancer-specific m

118 cant increase in suicide-specific mortality (SMR 6.85, 95% CI 2.22-15.98; p=0.002).

119 and from $3,200 to $7,100/kWe for a 225-MWe SMR.

120 estimates for a 45 megawatts-electric (MWe) SMR range from $4,000 to $16,300/kWe and from $3,200 to

121 We hypothesized that the Nef SMR binds a cellular protein involved in protein traffic

122 .9), but no difference was observed for NHL (SMR, 0.9; 95% CI, 0.4 to 2.1).

123 f CLL (SMR, 3.1; 95% CI, 2.2 to 4.3) or NHL (SMR, 1.9; 95% CI, 1.3 to 2.8).

124 f CLL (SMR, 2.8; 95% CI, 2.2 to 3.4) or NHL (SMR, 2.1; 95% CI, 1.7 to 2.6).

125 During the SMR and non-SMR periods of the night, no overall effect of sleep sta

126 the lowest mean energy expenditure) and non-SMR.

127 red with REM sleep (P < 0.01) during the non-SMR period of the night, was found.

128 metry and coimmunoprecipitation with a novel SMR-based peptide (SMRwt) that blocks exNef secretion an

129 cess to, engineering-economic assessments of SMR projects.

130 ity racial differences in the computation of SMR helps to clarify disparities in quality of health ca

131 y increased in patients having any degree of SMR compared with patients not having SMR (21 studies, 2

132 Patients with PPM had less regression of SMR following AVR compared with those with no PPM (chang

133 e relationship between PPM and regression of SMR following AVR for aortic valve stenosis.

134 PPM is associated with lesser regression of SMR following AVR.

135 und considerable overlap with the results of SMR analyses performed with expression QTL (eQTL) data.

136 To clarify the role of SMR in the outcomes of patients with ischemic or idiopat

137 e requirements, high precision, and speed of SMR measurements, the method may become a valuable new t

138 The functional diversity of SMRs underscores both the varied mechanisms of oncogenic

139 CMRs and natural logarithm of SMRs were pooled by the method of the inverse of the var

140 We ranked centers based on SMR and evaluated outcomes for patients transplanted the

141 its correlation with outcomes, mixed data on SMR and primary mitral regurgitation, studies not clearl

142 te publication data, studies lacking data on SMR grade and its correlation with outcomes, mixed data

143 ma that could be used to calculate an SIR or SMR in any flight-based occupation.

144 Overall SMR for death before age 75 (premature mortality) was 5.

145 The overall SMR for all-cause mortality was 1.61 (95% CI 1.23-2.12;

146 n women with NF1 age < 40 years; the overall SMR for breast cancer was 5.20 (95% CI, 2.38 to 9.88).

147 The overall SMR was 2.4 (95% CI 1.7 to 3.3).

148 pected for rescue and recovery participants (SMR 0.45, 95% CI 0.38-0.53) and non-rescue and non-recov

149 l similar to that of the general population (SMR 0.95, 95% CI 0.58-1.55) compared with those who were

150 in patients than in the general population (SMR 3.6, 95% CI 3.5-3.8), and occurred more in males (4.

151 evated compared with the Ontario population (SMR, 2.84 [95% CI, 2.61-3.07]).

152 o address this issue, we studied a maize PPR-SMR protein denoted PPR53 (GRMZM2G438524), which is orth

153 ps, the small multidrug resistance proteins (SMRs), consists of proteins of about 110 residues that n

154 summary-data-based Mendelian randomization (SMR), a method developed to identify variants pleiotropi

155 ch feeding history, standard metabolic rate (SMR) and aerobic scope (AS), interact to affect temperat

156 estimate individual standard metabolic rate (SMR) and the tendency to utilize aerial oxygen when alon

157 Flexibility in standard metabolic rate (SMR) may be particularly important since SMR reflects th

158 morphosis, increase standard metabolic rate (SMR), and elevate whole-body content of thyroid hormone

159 and separately for sleeping metabolic rate (SMR; ie, 3-h period during the night with the lowest mea

160 me to first SRE and skeletal morbidity rate (SMR).

161 her than expected (standard mortality ratio (SMR) = 1.1, 95% confidence interval (CI) = 1.02-1.20).

162 mesothelioma (standardized mortality ratio (SMR) = 2.85, 95% confidence interval (CI): 1.05, 6.20),

163 plots for the Standardised Mortality Ratio (SMR) based on the Poisson distribution were calculated u

164 exposure; and standardized mortality ratio (SMR) for suicide post-surgery.

165 timates of the standardised mortality ratio (SMR) or hazard ratios associated with type 1 diabetes, e

166 A center-level standardized mortality ratio (SMR) was constructed (ratio of observed to expected deat

167 population, a standardized mortality ratio (SMR) was used.

168 e ratio (SIR), standardized mortality ratio (SMR), or data on expected and observed cases of melanoma

169 mortality, and standardized mortality ratio (SMR).

170 as measured by standardized mortality ratio (SMR; SMR for CLL, 2.6; 95% CI, 2.3 to 3.0; SMR for NHL,

171 tcome measure, standardized mortality ratio [SMR]).

172 al population (standardized mortality ratio [SMR], 1.18; P = .25).

173 eater for men (standardized mortality ratio [SMR], 1.32 [95% CI, 1.18-1.48]) than for women (SMR, 1.1

174 ted mortality (standardized mortality ratio [SMR], 2.6 [95% CI, 1.8-3.7] for TIA, 3.9 [95% CI, 3.2-4.

175 dertaken, and standardised morbidity ratios (SMR) calculated, assessing morbidity prevalence relative

176 nd calculated standardized mortality ratios (SMR) for kidney transplant centers over five distinct er

177 Standardised mortality ratios (SMR) were calculated with New York City rates from 2000-

178 al estimates, standardized mortality ratios (SMR), and standard incidence ratios (SIR) for malignancy

179 Standardized morbidity ratios (SMRs) were estimated by comparing the observed rates of

180 Standardized mortality ratios (SMRs) and 95% confidence intervals (95% CIs) were determ

181 to calculate standardized mortality ratios (SMRs) and 95% confidence intervals.

182 Comparative standardized mortality ratios (SMRs) and causes of death were obtained from the Office

183 ty risk using standardized mortality ratios (SMRs) and marginal structural modeling.

184 ey calculated standardized mortality ratios (SMRs) and relative risks.

185 tality rates, standardised mortality ratios (SMRs) and relative survival.

186 alculated age-standardised mortality ratios (SMRs) and years of life lost (YLL), and we tested for as

187 dised and sex-standardised mortality ratios (SMRs) for all-cause mortality (SMR 1.14, 95% CI 0.65-1.8

188 We calculated standardised mortality ratios (SMRs) for all-cause, suicide-specific, and cancer-specif

189 Standardized mortality ratios (SMRs) for CVD and absolute excess risks (AERs; number of

190 s (CMRs), and standardised mortality ratios (SMRs) in MS, and estimated the rate of change of CMR and

191 , age-and-sex-standardised mortality ratios (SMRs) in people with severe mental illness were increase

192 Standardized mortality ratios (SMRs) reported by Medicare compare mortality at individu

193 We calculated standardised mortality ratios (SMRs) standardised by age, sex, and year, stratifying by

194 We calculated standardised mortality ratios (SMRs) to compare the mortality in the study populations

195 We used standardised mortality ratios (SMRs) to make comparisons with the general population.

196 andardized incidence-based mortality ratios (SMRs) using rates for the Norwegian population at large

197 os (SIRs) and standardized mortality ratios (SMRs) were calculated for selected cancer types.

198 Standardized mortality ratios (SMRs) were used to assess the 5-year and 10-year excess

199 record data, standardized mortality ratios (SMRs), relative SMRs (rSMRs), and proportional mortality

200 os (SIRs) and standardized mortality ratios (SMRs).

201 nd calculated standardized mortality ratios (SMRs).

202 ey calculated standardized mortality ratios (SMRs).

203 essed them as standardised mortality ratios (SMRs).

204 ulation using standardized mortality ratios (SMRs).

205 ntry to yield standardized mortality ratios (SMRs).

206 nd mortality (standardised mortality ratios [SMRs] and mortality rates).

207 ed costs of proposed small modular reactors (SMRs) were similar to those of Gen. IV systems.

208 Small modular reactors (SMRs), which could become part of a portfolio of carbon-

209 although the south Asian group had a reduced SMR for cancer mortality (0.49, 0.21-0.96).

210 In contrast, a reduced SMR with negligible CAMR and AHR was found in Rh/YIG hyb

211 ic cracker (FCC) and steam methane reformer (SMR) units, and alternative hydrogen production technolo

212 ef motif, the secretion modification region (SMR; amino acids 66 to 70), that is required for exNef s

213 ariably sized significantly mutated regions (SMRs).

214 function and secondary mitral regurgitation (SMR) are still controversial.

215 Secondary mitral regurgitation (SMR) is generally reduced after isolated aortic valve re

216 ence interval (CI): 1.14, 1.59; drug-related SMR: 4.60, 95% CI: 3.17, 6.46; HIV-related SMR: 1.54, 95

217 d SMR: 4.60, 95% CI: 3.17, 6.46; HIV-related SMR: 1.54, 95% CI: 1.03, 2.21); all-cause and HIV-relate

218 % CI: 1.03, 2.21); all-cause and HIV-related SMRs in other patterns were not statistically significan

219 arbor a carboxy-terminal small-MutS-related (SMR) domain, but the functions of the SMR appendage are

220 In the relative SMR analysis for applicators, the relative mortality rat

221 r the cohort's overall healthiness, relative SMRs were estimated by calculating the SMR for each caus

222 andardized mortality ratios (SMRs), relative SMRs (rSMRs), and proportional mortality ratios were cal

223 The Statistical Model Residual (SMR) can give information on additional sources of O3 th

224 e members of the small multidrug resistance (SMR) family that are composed of four transmembrane (TM)

225 ity of the suspended microchannel resonator (SMR) to distinguish between buoyant particles (e.g., sil

226 , we use a suspended microchannel resonator (SMR) to measure single-cell density, volume, and passage

227 ibrils by suspended microchannel resonators (SMR).

228 Suspended microchannel resonators (SMRs) are highly sensitive, batch-fabricated microcantil

229 Shear mode solidly mounted resonators (SMRs) are fabricated using an inclined c-axis ZnO grown

230 The respective SMRs in bipolar disorder were 6.47 (5.87-7.06) and 2.93

231 d that mortalin interacts with Nef via Nef's SMR motif and that this interaction is disrupted by the

232 The mean (SD) SMR was 0.46 (1.06) vs 0.50 (1.50) events per year in th

233 ostructured morphology completely over 10 SE-SMR cycles due to its intrinsic lack of a support compon

234 Here, SE-SMR was studied using a mixture containing a Ni-hydrotal

235 Sorbent-enhanced steam methane reforming (SE-SMR) is an emerging technology for the production of hig

236 members of the SIAMESE/SIAMESE-RELATED (SIM/SMR) class of cyclin-dependent kinase inhibitors were di

237 cific and strong activation of the three SIM/SMR genes in the meristems upon DNA stress, whereas over

238 te (SMR) may be particularly important since SMR reflects the minimal energetic cost of living and is

239 asured by standardized mortality ratio (SMR; SMR for CLL, 2.6; 95% CI, 2.3 to 3.0; SMR for NHL, 2.3;

240 rend in CMRs, all-cause, and gender-specific SMRs.

241 se variance weighting to obtain sex-specific SMRs and their pooled ratio (women to men) for all-cause

242 As such, SMR oligomerization sites should constitute viable targe

243 Summary SMR estimates for the International Classification of Di

244 The overall summary SMR of participants in any flight-based occupation was 1

245 The summary SMR for cabin crew was 0.90 (95% CI, 0.80-1.01; P = .97;

246 The summary SMR for pilots was 1.83 (95% CI, 1.27-2.63, P = .33; 4 r

247 95% CI, 1.03 to 1.78; n=54) but not surgery (SMR, 0.81; 95% CI, 0.60 to 1.07; n=50).

248 st meta-analysis to date to demonstrate that SMR, even when mild, correlates with adverse outcomes in

249 There was consensus that SMRs could be built and brought online about 2 y faster

250 The SMR declined with follow-up but was still 3-fold higher

251 The SMR for cancer death after solid-organ transplantation w

252 The SMR for circulatory disease was increased at 2.72 (1.88-

253 The SMR for suicide after GBP was increased among females (n

254 The SMR in the early HFOV group was 1.62 (95% CI, 1.31-2.01)

255 The SMR in the HFOV group was 2.00 (95% CI, 1.71-2.35) compa

256 The SMR of patients in group I was increased to 21.5 when co

257 The SMR of the FD fish was increased compared with the contr

258 The SMR was 4.3 (95% CI, 3.2-5.6) for women and 3.6 (95% CI,

259 The SMR was significantly decreased in pain syndromes (0.41

260 The SMR was significantly increased in those with a known re

261 In LQTS type 3, the SMR was increased between age 15 and 19 years (SMR, 5.8;

262 ctured linker is likely conserved across the SMR family to play an active role in mediating the confo

263 ath, using Kaplan-Meier methodology, and the SMR based on mortality data from the Social Security Dea

264 this period the MDA8 reached 83 ppbv and the SMR suggests a wildfire contribution of 19 ppbv to the M

265 ative SMRs were estimated by calculating the SMR for each cause relative to the SMR for all other cau

266 During the SMR and non-SMR periods of the night, no overall effect

267 Significant improvement in the SMR emerged after 3 or more preceding years of increasin

268 An unanswered question in the SMR field is how the dimerization domain (TM4) is couple

269 lated (SMR) domain, but the functions of the SMR appendage are unknown.

270 ut is known in multidrug transporters of the SMR family, and is suggestive of an evolutionary anteced

271 The pooled women-to-men ratio of the SMR for all-cause mortality was 1.37 (95% CI 1.21-1.56),

272 -dependent transcriptional activation of the SMR genes was confirmed by different ROS-inducing condit

273 Limitations of the SMR method are also discussed.

274 xtreme; the pooled women-to-men ratio of the SMR was 2.54 (95% CI 1.80-3.60).

275 arried out a structure-function study on the SMR protein EmrE using solid-state NMR spectroscopy in l

276 res is estimated to be 26 ppbv, based on the SMR, and 60 ppbv, based on WRF-Chem.

277 In schizophrenia, the SMR in those with lifetime substance use disorder was 8.

278 Still, the SMR of patients in group II increased to 3.67.

279 It is shown that the SMR system can potentially distinguish between silicone

280 ating the SMR for each cause relative to the SMR for all other causes.

281 The SMRs for female and male patients with RACU were 43.5 (9

282 st in those individuals that depressed their SMR most.

283 owth; those individuals that increased their SMR more in response to elevated food levels grew fastes

284 hybrid, large spin-Hall magne toresistance (SMR) along with a sizable conventional anisotropic magne

285 loped detailed technical descriptions of two SMR designs and then conduced elicitation interviews in

286 r more preceding years of increasing volume (SMR change -0.008; 95% CI -0.015, -0.002; P = 0.01).

287 hedules as factors that may make light water SMRs economically viable.

288 involve a large reactor and two light water SMRs.

289 When SMR was categorized as present or absent, all-cause mort

290 95% CI, 1.47-2.18; P < .001, I2 = 85%); when SMR was qualitatively graded, the incidence of all-cause

291 Finally, when SMR was quantitatively graded, it remained associated wi

292 e thought processes of experts involved with SMR design.

293 as significantly higher in the patients with SMR (17 studies, 26359 patients; risk ratio [RR],1.79; 9

294 reporting data on outcomes in patients with SMR were included.

295 efer temperatures that vary predictably with SMR and activity level, which are both plastic in respon

296 cause mortality in patients with and without SMR.

297 ], 1.32 [95% CI, 1.18-1.48]) than for women (SMR, 1.14 [95% CI, 0.80-1.63]).

298 ed with 2-fold increase in odds of worsening SMR over time (OR 2.14; 95% CI 1.07-4.26, P = 0.03).

299 R was increased between age 15 and 19 years (SMR, 5.8; 95% CI, 1.2-16.9).

300 ality was restricted to ages 20 to 39 years (SMR, 3.0; 95% CI, 1.3-6.0).

301 years, with a peak between 20 and 39 years (SMR, 3.8; 95% CI, 2.5-5.7).

302 ) and lower in patients older than 60 years (SMR, 1.88 [95% CI, 1.62-2.18]) but remained elevated com